Chendi Xie

Chendi Xie

Auto-generated profile, based on publicly available information

Chendi Xie

State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Biology, School of Life Sciences, Xiamen University, Xiamen, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
HZHui Zhou
Hui Zhou
DQDongmei Qin
Dongmei Qin
CXChendi Xie
Chendi Xie
JZJie Zha
Jie Zha
SJShuman Jia
Shuman Jia
JZJie Zha
Jie Zha
Purpose: Leukemic stem cells (LSC) are responsible for leukemia initiation, relapse, and therapeutic resistance. Therefore, the development of novel therapeutic approaches targeting LSCs is urgently needed for patients with acute myeloid leukemia (AML). Experimental Design: The LSC-like cell lines (KG-1α and Kasumi-1) and CD34+ primary AML cells purified from patients with AML (n = 23) treated with CS055 and/or chiglitazar and were analyzed for viability, death, and colony formation assay. We performed RNA sequencing, glutamate release, intracellular glutathione, lipid reactive oxygen species, transmission electron microscopy, and Western blotting assay and confirmed ferroptosis in LSC-like cells. The luciferase reporter, co-immunoprecipitation, histone deacetylase 3 (HDAC3)-shRNA/HDAC3/deacetylase-deficient LSC-like cell lines, histidine pull-down, and chromatin immunoprecipitation assays performed to clarify the molecular mechanism of CS055/chiglitazar in LSC-like cells. We also established cell-derived xenograft and patient-derived xenograft mouse models to evaluate the therapeutic efficacy of CS055/chiglitazar against AML in vivo. Results: We report that the HDAC inhibitor CS055, in combination with peroxisome proliferator–activated receptor pan-agonist (chiglitazar), synergistically targets leukemic stem-like cells from leukemia cell lines and patient samples while sparing normal hematopoietic progenitor cells. Mechanistically, chiglitazar enhances the inhibitory effect of CS055 on HDAC3 and induces ferroptosis in LSC-like cells by downregulating the expression of ferroptosis suppressor SLC7A11. In fact, the inhibition of HDAC3 increases H3K27AC levels in the promoter region of activating transcription factor 3 (ATF3), a transcriptional repressor of the SLC7A11 gene, and upregulates the expression of ATF3. In contrast, ATF4, a SLC7A11 activator, is suppressed by HDAC3 inhibition. Conclusions: Our findings suggest that treatment with CS055 combined with chiglitazar will target LSCs by inducing ferroptosis and may confer an effective approach for the treatment of AML.

2 December 2024
Verified
Other
Open access
HZHui Zhou
Hui Zhou
DQDongmei Qin
Dongmei Qin
CXChendi Xie
Chendi Xie
JZJie Zha
Jie Zha
SJShuman Jia
Shuman Jia
JZJie Zha
Jie Zha
Purpose:Leukemic stem cells (LSC) are responsible for leukemia initiation, relapse, and therapeutic resistance. Therefore, the development of novel therapeutic approaches targeting LSCs is urgently needed for patients with acute myeloid leukemia (AML).Experimental Design:The LSC-like cell lines (KG-1α and Kasumi-1) and CD34+ primary AML cells purified from patients with AML (n = 23) treated with CS055 and/or chiglitazar and were analyzed for viability, death, and colony formation assay. We performed RNA sequencing, glutamate release, intracellular glutathione, lipid reactive oxygen species, transmission electron microscopy, and Western blotting assay and confirmed ferroptosis in LSC-like cells. The luciferase reporter, co-immunoprecipitation, histone deacetylase 3 (HDAC3)-shRNA/HDAC3/deacetylase-deficient LSC-like cell lines, histidine pull-down, and chromatin immunoprecipitation assays performed to clarify the molecular mechanism of CS055/chiglitazar in LSC-like cells. We also established cell-derived xenograft and patient-derived xenograft mouse models to evaluate the therapeutic efficacy of CS055/chiglitazar against AML in vivo.Results:We report that the HDAC inhibitor CS055, in combination with peroxisome proliferator–activated receptor pan-agonist (chiglitazar), synergistically targets leukemic stem-like cells from leukemia cell lines and patient samples while sparing normal hematopoietic progenitor cells. Mechanistically, chiglitazar enhances the inhibitory effect of CS055 on HDAC3 and induces ferroptosis in LSC-like cells by downregulating the expression of ferroptosis suppressor SLC7A11. In fact, the inhibition of HDAC3 increases H3K27AC levels in the promoter region of activating transcription factor 3 (ATF3), a transcriptional repressor of the SLC7A11 gene, and upregulates the expression of ATF3. In contrast, ATF4, a SLC7A11 activator, is suppressed by HDAC3 inhibition.Conclusions:Our findings suggest that treatment with CS055 combined with chiglitazar will target LSCs by inducing ferroptosis and may confer an effective approach for the treatment of AML.

2 December 2024
Verified
Other
Open access
HZHui Zhou
Hui Zhou
DQDongmei Qin
Dongmei Qin
CXChendi Xie
Chendi Xie
JZJie Zha
Jie Zha
SJShuman Jia
Shuman Jia
JZJie Zha
Jie Zha
Supplementary Figure S3. (A) The statistical results of fluorescence intensity in CDX mice models (n = 5/group). (B-C) Flow cytometry analysis of the percentage of hCD45+ cells in bone marrow (B) and spleen (C) (n=3/group). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

2 December 2024
Verified
Other
Open access
PDF file
HZHui Zhou
Hui Zhou
DQDongmei Qin
Dongmei Qin
CXChendi Xie
Chendi Xie
JZJie Zha
Jie Zha
SJShuman Jia
Shuman Jia
JZJie Zha
Jie Zha
Supplementary Figure S9. (A-B) Representative data for flow cytometric analysis of mCD45/hCD34 staining in the spleen (A) and bone marrow (B). (C) Flow cytometry analysis of human CD34+ AML cells sorted from bone marrow of PDX#1 and PDX#2 mice by human CD34 Nanobeads.

2 December 2024
Verified
Other
Open access
HZHui Zhou
Hui Zhou
DQDongmei Qin
Dongmei Qin
CXChendi Xie
Chendi Xie
JZJie Zha
Jie Zha
SJShuman Jia
Shuman Jia
JZJie Zha
Jie Zha
Supplementary Figure S10. A proposed mechanism for the CS055/chiglitazar-induced ferroptosis-like cell death in LSC-like cells by blocking the HDAC3-SLC7A11-GSH-GPX4 pathway.

2 December 2024
Verified
Other
Open access
HZHui Zhou
Hui Zhou
DQDongmei Qin
Dongmei Qin
CXChendi Xie
Chendi Xie
JZJie Zha
Jie Zha
SJShuman Jia
Shuman Jia
JZJie Zha
Jie Zha
Supplementary Figure S2. The combination of CS055 and chiglitazar synergistic inhibited AML progression in vivo. (A) Schematic outline of the CDX models. (B) CS055 and Chiglitazar were synergistic inhibited the AML progression in CDX mice models (n = 5/group). The AML progression was measured by the living imaging system. (C) Image and weight of representative spleens from CDX mice models (n = 3/group). (D-E) The human CD45 positive cell insulation rate was measured by flow cytometry in bone marrow (D) and spleen (E) (n = 3/group). (F) The combination of CS055 and chiglitazar improved the survival of CDX mice models (n = 5/group), and animal survival was analyzed using the Kaplan-Meier survival curve. (G) Statistical results of body weight from CDX mice models (n = 5/group). *P < 0.05, **P < 0.01.